Nico J. Diederich

Prof. Dr. Nico J. Diederich


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Nature Reviews Neurology
Verified
Journal Article
Closed access
NDNico J. Diederich
Nico J. Diederich
GFGilles Fénelon
Gilles Fénelon
GSGlenn Stebbins
Glenn Stebbins
CGChristopher G. Goetz
Christopher G. Goetz

14 October 2004 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
NDNico J. Diederich
Nico J. Diederich
CGChristopher G. Goetz
Christopher G. Goetz
GSGlenn T. Stebbins
Glenn T. Stebbins

21 July 2005 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
NDNico J. Diederich
Nico J. Diederich
KKKarin Kalteis
Karin Kalteis
MSMara Stamenkovic
Mara Stamenkovic
VPVannina Pieri
Vannina Pieri
FAFrançois Alesch
François Alesch

8 July 2005 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
NDNico J. Diederich
Nico J. Diederich
MVMichel T Vaillant
Michel T Vaillant
MLMike Leischen
Mike Leischen
GMGiovanna Mancuso
Giovanna Mancuso
SGSerge Golinval
Serge Golinval
MSMarc Schlesser
Marc Schlesser

1 July 2005 in Sleep Medicine
Verified
Journal Article
Closed access
NDNico J. Diederich
Nico J. Diederich
MVMichel T Vaillant
Michel T Vaillant
GMG Mancuso
G Mancuso
PLP Lyen
P Lyen
JTJ Tiete
J Tiete

26 August 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
NDNico J. Diederich
Nico J. Diederich
CGChristopher G. Goetz
Christopher G. Goetz
Placebo (PL) treatment is a method utilized as a control condition in clinical trials. A positive placebo response is seen in up to 50% of patients with Parkinson disease (PD), pain syndromes, and depression. The response is more pronounced with invasive procedures or advanced disease. Physiologic and biochemical changes have been studied in an effort to understand the mechanisms underlying placebo-related clinical improvement. In PD, objective clinical improvements in parkinsonism correlate with dopaminergic activation of the striatum, documented by PET and with changes in cell firings of the subthalamic nucleus documented by single cell recordings. Dopaminergic pathways mediating reward may underlie PL-mediated improvement in PD. In pain syndromes, endogenous opioid release triggered by cortical activation, especially the rostral anterior cingulated cortex, is associated with PL-related analgesia and can be reversed by opioid antagonists. Covert treatment of an analgesic is less effective than overt treatment, suggesting an expectation component to clinical response. In depression, PL partially imitates selective serotonin reuptake inhibitor–mediated brain activation. Diseases lacking major “top-down” or cortically based regulation may be less prone to PL-related improvement.